Premium
Effects of FK506 on an experimental model of colitis in rats
Author(s) -
HOSHINO H.,
GOTO H.,
SUGIYAMA S.,
HAYAKAWA T.,
OZAWA T.
Publication year - 1995
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1995.tb00385.x
Subject(s) - myeloperoxidase , colitis , superoxide , medicine , pharmacology , endocrinology , chemistry , biochemistry , inflammation , enzyme
SUMMARY Aim : To assess the effects of FK506, a newly developed immunosuppressant, on experimental colitis in rats. Methods : Experimental colitis was induced by a single colonic instillation of hapten 2,4,6‐trinitrobenzene sulphonic acid (TNB) in anaesthetized rats. Rats received 30 mg TNB dissolved in 0.25 mL of 50% ethanol, and were sacrificed on day 5 following 4 days dosing with FK506 (0.25, 0.5, 1.0, 2.0 mg/kg, s.c.) or vehicle. Mucosal prostanoid concentrations were determined using high performance liquid chromotography. Tissue myeloperoxidase activities were measured. The effects of FK506 on superoxide radical formation by neutrophils in both rats and humans were also estimated in vitro. Results: Administration of FK506 significantly reduced the colonic damage in a dose‐dependent manner. Activities of myeloperoxidase and concentrations of 6‐keto‐prostaglandin Fl 1α (6‐keto‐PGF 1α , PGF 2α and PGE 2 in colonic tissue increased significantly following induction of experimental colitis, however, FK506 did not affect these changes. FK506 reduced stimulant‐induced superoxide radical formation by neutrophils in rats and humans. Conclusion : FK506 decreased superoxide radical generation by neutrophils, which might contribute to the lessening of colonic damage in this model.